| Byetta (exenatide) / AstraZeneca |
COCONUT, NCT04307797: Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes |
|
|
| Recruiting | 4 | 16 | Europe | 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Byetta, Glucagon 12.5ng/kg/min and 0.9% saline, Glucagon 12.5ng/kg/min | Cambridge University Hospitals NHS Foundation Trust, Antaros Medical | Type 2 Diabetes, Obesity | 01/23 | 01/24 | | |
NCT01107717: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM |
|
|
| Completed | 4 | 521 | US | metformin\pioglitazone\exenatide, metformin, glyburide and glargine | The University of Texas Health Science Center at San Antonio, American Diabetes Association, Amylin Pharmaceuticals, LLC., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes | 02/23 | 02/23 | | |
|
NCT00679042: Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol |
|
|
| Active, not recruiting | 3 | 21 | US | Islets of Langerhans transplantation, Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®), Exenatide (Byetta®) | CellTrans Inc. | Type 1 Diabetes Mellitus | 07/17 | 06/26 | | |
| Not yet recruiting | 3 | 270 | RoW | Exendin-4 Fc fusion protein injection, JY09(1.2mg), JY09(2.4mg), Placebo, Injection mimetic | Beijing Dongfang Biotech Co., Ltd. | Type 2 Diabetes Mellitus | 04/25 | 12/25 | | |
DFBT-JY09-DM-302, NCT06257966: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin |
|
|
| Not yet recruiting | 3 | 600 | RoW | Exendin-4 Fc fusion protein injection(1.2mg）, JY09(1.2mg), Exendin-4 Fc fusion protein injection（2.4mg）, JY09(2.4mg), Dulaglutide, Metformin | Beijing Dongfang Biotech Co., Ltd. | Type2 Diabetes Mellitus | 04/25 | 12/25 | | |
2011-002780-16: A study of efficacy and safety of the glucose lowering drug Exenatide on patients with suspected acute stroke and hyperglycemia |
|
|
| Ongoing | 2 | 100 | Europe | Byetta, Novorapid, A10AB05, Solution for injection in pre-filled pen, Byetta, Novorapid | Karolinska Institutet, Karolinska institutet Södersjukhuset | Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of Byetta or standard care., Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of the glucose lowering drug Byetta or standard care against hyperglycemia., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-004115-27: Identification and clinical relevance of oxytocin deficient status: GLP1 study Identificación y relevancia clÃnica de un estado deficiente de oxitocina: Estudio GLP1 |
|
|
| Ongoing | 2 | 52 | Europe | Solution for injection in pre-filled pen, Byetta | Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau, Instituto de Salud Carlos III | Hypopituitarism Hipopituitarismo, Hypopituitarism Hipopituitarismo, Diseases [C] - Hormonal diseases [C19] | | | | |
NCT06247748: Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects |
|
|
| Active, not recruiting | 1 | 28 | RoW | Exendin-4 Fc fusion protein (JY09) injection, JY09, Metformin Hydrochloride tablet, Metformin, Rosuvastatin calcium tablets, Rosuvastatin, Digoxin tablet, digoxin | Beijing Dongfang Biotech Co., Ltd. | Diabetes Mellitus, Type 2, Overweight | 04/24 | 04/24 | | |